Publisher： John Wiley & Sons Inc
E-ISSN： 1365-2710|40|3|349-352
ISSN： 0269-4727
Source： JOURNAL OF CLINICAL PHARMACY & THERAPEUTICS, Vol.40, Iss.3, 2015-06, pp. : 349-352
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
SummaryWhat is known and objectiveAspirin is an important drug in acute coronary syndromes (ACS) and percutaneous coronary interventions (PCI). However, its use is contraindicated in patients with glucose‐6‐phosphate dehydrogenase (G6PD) deficiency (risk for haemolytic anaemia). We report the management of 2 patients with class II G6PD deficiency and non‐ST‐segment elevation ACS (NSTE‐ACS).Case descriptionThe two patients were safely and efficiently treated with dual antiplatelet treatment (DAPT, aspirin plus ticagrelor) and PCI using new‐generation drug‐eluting stent (DES) despite G6PD deficiency.What is new and conclusionNSTE‐ACS management with DAPT and DES is probably safe and effective in class II G6PD‐deficient patients.
Related content
Access to resources
Recommend
Acta Haematologica, Vol. 101, Iss. 3, 1999-05 ,pp. :
Acute Hemolytic Anemia in Glucose-6-Phosphate Dehydrogenase Deficiency Complicated by
Acta Haematologica, Vol. 130, Iss. 4, 2013-08 ,pp. :
By Douzinas Emmanuel E. Flevari Katerina Andrianakis Ilias Betrosian Alex P.
Scandinavian Journal of Infectious Diseases, Vol. 42, Iss. 1, 2010-12 ,pp. :